Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Antipodes China Fund

Fund overview

The Antipodes China Fund is an actively managed long-only equities fund focused on companies across a range of market capitalisations listed in Hong Kong, Mainland China, Macau, and Taiwan (Greater China).

The Fund may also invest in companies listed on other exchanges that have significant assets, investments, production activities, trading, or other business interests in the Greater China region, or that derive a significant portion of their revenue from the region.

The Fund combines rigorous fundamental research with disciplined stock selection to identify attractively valued opportunities, targeting long-term capital growth for investors who are willing to accept higher volatility.

This product is classified as a Hedge Fund under ASIC Regulatory Guide RG240 and may have complex features. It is likely to be suitable for investors who have received personal advice.

Ratings

The Antipodes China Fund has been rated “Approved” by Zenith Investment Partners and “Investment Grade” by Lonsec Research.
 

Performance chart

Cumulative performance (over selected time horizon)

Returns greater than 1 year are annualised. Past performance is no indication of future performance. Calculations are based on exit price with distributions reinvested.

Net performance

wpDataTable with provided ID not found!
Returns greater than 1 year are annualised. Past performance is no indication of future performance. 1Inception is 28 October 2005. 2Benchmark is MSCI China Index (net div.).

The Fund was previously known as the Premium China Fund. Antipodes Partners Limited became the Investment Manager of the Fund effective 22 April 2024.

Key facts

1The portfolio allocation ranges provided are indicative only. The Fund will be rebalanced within a reasonable period of time should the exposure move outside these ranges.

The publication of unit prices from 1st July 2025 onwards will be delayed while annual distribution amounts are finalised. The unit prices for 30th June 2025 are cum distribution and are reflective of fund performance to that date.

Unit price history
Distribution history
Portfolio profile as at 31st October 2026
Top 10 equity longs (%)
Sector exposure (%)2
Regional exposure (%)1, 3

1 Where possible, regions, countries and currencies classified on a look through basis. 2 GICS Classification. 3 Antipodes Partners classification.

For historical reports, please contact the Antipodes team
For historical reports, please contact the Antipodes team
Invest

If you are applying using paper application forms, the minimum investment in the Antipodes China Fund is $25,000 for
new investors and $10,000 for existing investors.


Who may invest in the fund

This fund is open to investors from Australia and New Zealand.


Important information

It is a legal requirement to download and read the Product Disclosure Statement before proceeding and
we recommend that you consult a licensed financial advisor before making investment decisions.

Download Product Disclosure Statement (PDS).

Download Product Disclosure Statement (PDS) – NZ.

Download Target Market Determination (TMD).


Apply online

The application below allows you to invest in the Antipodes China Fund.

If you are applying using paper application forms, the minimum investment in the Antipodes China Fund
is $25,000 for new investors and $10,000 for existing investors.

Apply online


Apply via a paper form

Purchase, top-up or sell a managed fund investment the familiar way.

  1. Download an application form here
  2. Complete the application form & sign
  3. Provide certified copies of your identity to verify your identity
  4. Email service@pinnacleinvestment.com

Download an application form


Benefits of investing in the Antipodes China Fund

  • Targeted exposure: Access a carefully selected portfolio of Chinese and China-related companies often unavailable to retail investors.
  • Professional management: Experienced team leveraging a disciplined investment process aimed at achieving absolute returns above the benchmark over a full market cycle.
  • Aligned interests: Antipodes is majority owned by its investment team with a performance culture underpinned by sensible incentives, ensuring our goals align with yours.
  • Robust investment process: Comprehensive, integrated investment approach and process.

Who is this fund for?

  • Investors seeking long-term capital growth through exposure to Chinese equities.
  • Those comfortable with high to very high risk and a minimum investment horizon timeframe of 5 years.
  • Investors looking to use the fund as a satellite to minor portfolio allocation within a diversified investment portfolio.

Meet the Portfolio Manager

Key fund information

Strategy

China Equity

Strategy inception date

October 2005

Investment objective

The Fund aims to provide long-term capital growth over a three-to-five year horizon

Benchmark

MSCI China Free Index (denominated in Hong Kong dollars and converted into Australian dollars)

Suggested minimum investment period

5 years

Minimum initial investment

A$25,000

Management fee

1.28% p.a. of the NAV of the Fund

Performance fee

15% of net return in excess of the MSCI China Free Index

Frequently asked questions

Are China stocks a good investment?

China stocks can offer attractive long-term investment opportunities due to the size of the economy, growing middle class, and ongoing innovation across sectors such as technology, healthcare, and consumer services. However, investing in Chinese equities can involve higher volatility and regulatory risk, making a long-term investment horizon and professional management important considerations.

At times, China stocks may trade at valuations below their long-term fundamentals due to market sentiment, policy uncertainty, or geopolitical factors. These conditions can create opportunities for active managers to identify high-quality Chinese companies trading below their intrinsic value, although valuations and opportunities vary over time.

Australians can invest in Chinese stocks through professionally managed investment funds offered by Antipodes. The Antipodes China Fund provides investors with diversified exposure to Chinese and China-related equities, backed by active management, rigorous research, and ongoing portfolio oversight. Investors can access the fund directly or via a financial adviser, allowing them to gain exposure to China’s equity markets without the complexity of investing in individual stocks.

The Antipodes China Fund focuses specifically on Chinese and China-related companies, offering targeted exposure to China’s equity markets. In contrast, the Antipodes Asia Fund provides broader diversification across the Asia (ex-Japan) region, investing in companies across multiple countries. The Antipodes China Fund may experience higher volatility due to its concentrated regional focus.

Important information

This information has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Antipodes China Fund (ARSN 116 380 771) (‘Fund’). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Antipodes China Fund.  MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526). 

This website contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.  

Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks  referred to  may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information.  Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at www.antipodes.com or by calling 1300 097 995.  

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating assigned Antipodes China Fund (MAQ0441AU) – October 2025 referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. 

The rating issued 25/03/2026 for the Antipodes China Fund (MAQ0441AU) is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2026 Lonsec. All rights reserved.

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X